Skip to main content

Table 3 Change in PHQ-9 and PCL-5 scores at Day 5 in the population without data imputation

From: Delivering transcutaneous auricular neurostimulation (tAN) to improve symptoms associated with opioid withdrawal: results from a prospective clinical trial

Questionnaire

n1

Mean (SD) Reduction

95% CI

Percent Reduction

P value2

Percentage of Participants with Clinically Meaningful Reduction (n/N%)3

PHQ-9

14

5.1 (6.0)

[8.532, 1.611]

29.5 (35.0)%

0.0074

6 (42.9%)

PCL-5

14

9.8 (8.9)

[14.95, 4.621]

29.8 (32.7)%

0.0013

5 (35.7%)

  1. 1Excludes one participant with score over 2 standard deviations above the mean
  2. 2Two-tailed, paired t-test
  3. 3Defined as at least a 5-point decrease for PHQ-9 and at least a 10-point decrease for PCL-5
Back to article page

Bioelectronic Medicine

ISSN: 2332-8886